Breaking Down SG&A Expenses: Viatris Inc. vs PTC Therapeutics, Inc.

A Comparative Analysis of SG&A Expenses: Viatris Inc. vs PTC Therapeutics, Inc.

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Viatris Inc. and PTC Therapeutics, Inc. from 2014 to 2023. Over this period, Viatris Inc. consistently outpaced PTC Therapeutics, Inc. in SG&A spending, with an average annual expense of approximately $3 billion, compared to PTC's $189 million. Notably, Viatris's SG&A expenses peaked in 2023, reaching nearly $4.65 billion, a 210% increase from 2014. Meanwhile, PTC Therapeutics saw a more modest growth, with expenses rising by 642% over the same period. This disparity highlights Viatris's expansive operational scale and strategic investments in administrative functions. As the industry continues to grow, monitoring these financial trends offers valuable insights into each company's strategic priorities and market positioning.